Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14925534 | 0.86 | PRKDC (0.36) | PRKDC | |
| SCHEMBL16327923 | 0.76 | PNMT (0.52) | FBP1 | |
| SCHEMBL2737322 | 0.73 | ALDH1A1 (0.49) | — | |
| SCHEMBL12090941 | 0.73 | ALDH1A1 (0.45) | — | |
| SCHEMBL18723671 | 0.73 | FBP1 (0.35) | FBP1 | |
| SCHEMBL12636655 | 0.73 | PNMT (0.44) | — | |
| SCHEMBL31035824 | 0.73 | GRIN2B (0.37) | FBP1 | |
| SCHEMBL18197636 | 0.73 | KCNH2 (0.35) | FBP1 | |
| SCHEMBL24342158 | 0.72 | FBP1 (0.34) | FBP1 | |
| SCHEMBL16809691 | 0.72 | FBP1 (0.34) | FBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10280169-B2 | Biaryl bruton's tyrosine kinase inhibitors | BIOGEN MA INC. (US) | 2019-05-07 | — | — | US | disclosed |
| US-20160340322-A1 | SUBSTITUTED TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-11-24 | — | — | US | disclosed |
| EP-3085695-A1 | SUBSTITUTED TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | Nissan Chemical Industries, Ltd. (JP) | 2016-10-26 | — | — | EP | disclosed |
| WO-2015093534-A1 | SUBSTITUTED TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | 日産化学工業株式会社 | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160340322-A1 | SUBSTITUTED TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | CACNA1E, CACNA1I, CACNA1G | PRKDC 4577/4885FBP1 4164/4885 |
| US-10280169-B2 | Biaryl bruton's tyrosine kinase inhibitors | ABL1, BTK, LYN | PRKDC 36/4885FBP1 2719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.